The 5-HT7 receptor (5-HT7R) is involved in a broad range of physiological conditions and disorders. Currently, there is no validated clinical positron emission tomography (PET) tracer available; however, we have… Click to show full abstract
The 5-HT7 receptor (5-HT7R) is involved in a broad range of physiological conditions and disorders. Currently, there is no validated clinical positron emission tomography (PET) tracer available; however, we have recently developed a promising 11C-labeled candidate. In this project, we aimed to further extend our efforts and develop an 18F-labeled derivative, coined [18F]ENL30. Fluorine-18 has several advantages over carbon-11 especially within the preclinical phase, where a long half-life usually increases evaluation throughput. ENL30 was successfully synthesized in a low albeit sufficient overall yield. Radiolabeling succeeded with a radiochemical yield of approximately 4.5%. Subsequent preclinical PET studies revealed that [18F]ENL30 binds specifically to the 5-HT7R but suffered from affinity to σ-receptors. Additionally, we identified [18F]ENL30 to be a P-gp substrate in rats. However, we believe that [18F]ENL30 may prove to be valuable in higher species that exhibit decreased P-gp dependency. If requi...
               
Click one of the above tabs to view related content.